• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Conmed pulls 2022 guidance due to software implementation

Conmed pulls 2022 guidance due to software implementation

November 15, 2022 By Sean Whooley

ConMed logoConmed (NYSE:CNMD) announced today that it is withdrawing its full-year outlook over problems implementing software at its main distribution facility.

Largo, Florida-based Conmed last month issued its guidance with a reduction from previous projections. This came on the back of an underwhelming third-quarter performance that saw its stock dip by nearly 8%. However, shares of CNMD have been on the rise since then.

CNMD shares ticked up 1.3% at $90.24 apiece in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up more than 6%.

More about Conmed pulling is 2022 guidance

In October, the company cut its now withdrawn guidance for the full year, with the high end of its EPS expectations falling particularly far. It projected adjusted EPS to fall between $3.21 and $3.28. The company previously projected a range of $3.25 to $3.45. However, the low end of its revenue guidance rose. The company said it expected $1.1 billion and $1.115 billion for the year. The high end fell from the previously touted range of between $1.095 billion and $1.140 billion.

Conmed attributed its guidance withdrawal to the implementation of new software. It designed the software to increase the efficiency and performance of its primary distribution facility. However, the implementation created shipping disruptions that lasted longer than originally expected.

The company said it is unable fully assess the impact on its fourth-quarter sales and profitability. It continues to incur costs while working to reduce the shipping backlog. Daily shipment volumes returned to normal levels, with the backlog reduced from a peak of $35 million last week to $28 million today.

Conmed believes it will ship the backlog of open orders in the coming weeks. It anticipates a limited impact to business performance in the fourth quarter.

The company issued its 2023 financial outlook. It expects revenue between $1.17 billion and $1.23 billion. Conmed projects adjusted earnings per share to range between $3.20 and $3.50 in 2023.

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, News Well, Orthopedics, Surgical, Wall Street Beat Tagged With: Conmed, supply chain

More recent news

  • Medtronic announces a company president
  • Medtronic nets CE mark for Vitalis family of conduction system pacemakers
  • E2’s pulmonary embolism platform claims two FDA clearances
  • Resmed to launch AirTouch F40 full-face fabric CPAP mask in US
  • Paradromics taps Siemens Healthineers to develop scalable BCI imaging

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy